Scarica l'app Stockscreener
2.43
5.08%
-0.13
Dopo l'orario di chiusura:
2.43
Precedente Chiudi:
$2.56
Aprire:
$2.55
Volume 24 ore:
504.53K
Relative Volume:
0.73
Capitalizzazione di mercato:
$181.42M
Reddito:
$6.96M
Utile/perdita netta:
$-46.51M
Rapporto P/E:
-14.16
EPS:
-0.1716
Flusso di cassa netto:
$-37.99M
1 W Prestazione:
-0.82%
1M Prestazione:
+35.00%
6M Prestazione:
-80.31%
1 anno Prestazione:
-86.57%
Intervallo 1D:
$2.40
$2.60
Intervallo di 1 settimana:
$2.305
$2.649
Portata 52W:
$1.60
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Confronta CATX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.43 | 181.42M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Perspective Therapeutics Inc (AMEX: CATX): Down -84.76% In 2025, Outlook Remains Negative - Stocksregister
Legal & General Group Plc Has $155,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times
JPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors - marketscreener.com
Perspective Therapeutics (CATX) Launches Initial Patient Treatme - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors - The Manila Times
Groundbreaking Cancer Treatment Trial Launches: Perspective's FAP-α Targeted Alpha Therapy Shows Promise - Stock Titan
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Perspective Therapeutics Inc (CATX) - Sete News
A company insider recently bought 22,026 shares of Perspective Therapeutics Inc [CATX]. Should You Buy? - knoxdaily.com
Perspective Therapeutics Inc (CATX)’s stock rises to 2.33 per share - uspostnews.com
Perspective Therapeutics Announces Acceptance of VMT-?-NET and V - GuruFocus
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - The Manila Times
Perspective Therapeutics Announces Acceptance of Key Radiopharmaceutical Data for Presentation at ASCO 2025 Annual Meeting - Nasdaq
Major Breakthrough: Perspective Therapeutics to Present Novel Cancer Treatment Data at ASCO 2025 - Stock Titan
CATX Stock on the Rise: A Promising Investment - investchronicle.com
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR - The Globe and Mail
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | CATX Stock News - GuruFocus
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - The Manila Times
Perspective Therapeutics, Inc. to Announce Q1 2025 Financial Results and Business Update on May 12, 2025 - Nasdaq
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial - Bluefield Daily Telegraph
Perspective Therapeutics to Provide Business Highlights and Repo - GuruFocus
Arrowstreet Capital Limited Partnership Has $117,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
KLP Kapitalforvaltning AS Invests $79,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - MarketBeat
Perspective Therapeutics (PSTH) Advances Trial for Melanoma Trea - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with [212 - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy - MarketScreener
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - MarketScreener
Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial - Stock Titan
Is Now The Time To Invest In Perspective Therapeutics (NYSE:CATX) - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) Given New $10.00 Price Target at Truist Financial - Defense World
Truist cuts Perspective Therapeutics target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist cuts Perspective Therapeutics target to $10, maintains Buy - Investing.com
Paraganglioma Treatment Market Size in 7MM is expected to grow - openPR.com
Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating - marketscreener.com
CATX stock touches 52-week low at $1.87 amid market challenges - Investing.com Australia
CATX stock touches 52-week low at $1.87 amid market challenges By Investing.com - Investing.com South Africa
What is HC Wainwright’s Estimate for CATX Q2 Earnings? - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Pheochromocytomas and Paragangliomas Treatment Market Size - openPR.com
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective Therapeutics director Robert Williamson buys $132,151 in stock - Investing.com Australia
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock - Investing.com Australia
Perspective Therapeutics director Lori Woods acquires $49,999 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.62%
0.20%
Capitalizzazione:
|
Volume (24 ore):